Exploring Novel Methods to Achieve Systemic Delivery of SMN for Treatment of Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is an inherited neurodegenerative disease caused by insufficient levels of the survival motor neuron protein (SMN), leading to progressive deterioration of α-motor neurons, onset of muscle atrophy and, in severe disease, death. We investigated whether reducing the size...
Main Author: | McFall, Emily |
---|---|
Other Authors: | Parks, Robin |
Language: | en |
Published: |
Université d'Ottawa / University of Ottawa
2014
|
Subjects: | |
Online Access: | http://hdl.handle.net/10393/31803 http://dx.doi.org/10.20381/ruor-6563 |
Similar Items
-
Development of a Protein-Based Therapy for the Treatment of Spinal Muscular Atrophy
by: Burns, Joseph
Published: (2014) -
Development of a Protein-Based Therapy for the Treatment of Spinal Muscular Atrophy
by: Burns, Joseph
Published: (2014) -
Two-way Approach to Spinal Muscular Atrophy Therapy Development
by: Goulet, Benoit
Published: (2013) -
Two-way Approach to Spinal Muscular Atrophy Therapy Development
by: Goulet, Benoit
Published: (2013) -
The Need for SMN-Independent Treatments of Spinal Muscular Atrophy (SMA) to Complement SMN-Enhancing Drugs
by: Niko Hensel, et al.
Published: (2020-02-01)